Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

Prostate cancer is the second most common cancer affecting men globally, with diagnostic methods and risk assessment ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

Genetically predicted rheumatoid arthritis (RA) is causally associated with prostate cancer (PCa), according to a study ...

Two abstracts on Clarity’s diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium ...

Traditional approaches to prostate cancer screening involve blood tests, MRI, and biopsies. However, in addition to being ...

A test for pee-based markers of prostate cancer has previously relied on an uncomfortable first step. A new study has ...

Genomic tests are revolutionizing prostate cancer care, enabling precise, personalized treatment tailored to each patient.

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic ...

Tests do not consistently influence risk classification or treatment decisions; authors call for well-designed trials on role of GC tests in newly diagnosed PCa ...